Avapritinib for treating inadequately controlled moderate to severe indolent systemic mastocytosis [ID6578]

  • In development
  • GID-TA11772
  • Expected publication date: 
To appraise the clinical and cost effectiveness of Avapritinib within its marketing authorisation for treating systemic mastocytosis ID6578